Friday - January 23, 2026

Category Archives: Marketing & Sales

Myasthenia Gravis Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Alpine Immune Science, Toleranzia, Cabaletta Bio, Rallybio, Alexion

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Myasthenia Gravis pipeline constitutes 20+ key companies continuously working towards developing 22+ Myasthenia Gravis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes … Continue reading →

Dry Eye Disease Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Laboratorios Sophia, Iolyx Therapeutics, Oculis Pharma, HanAll BioPharma

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Dry Eye Disease pipeline constitutes 50+ key companies continuously working towards developing 60+ Dry Eye Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and … Continue reading →

Charcot Marie Tooth Disease Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Pharnext SA, MedDay Pharma, HELIXMITH, ENCell, Chong Kun Dang Pharm

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Charcot Marie Tooth Disease pipeline constitutes 10+ key companies continuously working towards developing 15+ Charcot Marie Tooth Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of … Continue reading →

Giant-Cell Arteritis Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | AbbVie, Novartis, CSL, Kiniksa Pharma, Eli Lilly, Roche, Johnson & Johnson, MorphoSys AG

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Giant-Cell Arteritis pipeline constitutes 6+ key companies continuously working towards developing 6+ Giant-Cell Arteritis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes … Continue reading →

Verrica’s VP-102 Advances Dermatology Care: First Patient Dosed in Global Phase 3 Common Warts Program

Verrica Pharmaceuticals doses first patient in global Phase 3 VP-102 trial for common warts, expanding beyond molluscum contagiosum treatment.   Verrica Pharmaceuticals Inc. has reached a key clinical milestone with the first patient dosed in its global Phase-3 clinical development … Continue reading →

Parkinson’s Disease Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | AbbVie, Pfizer, Novartis, F. Roche, Kissei Pharma, AstraZeneca, Prevail

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Parkinson’s Disease pipeline constitutes 80+ key companies continuously working towards developing 100+ Parkinson’s Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes … Continue reading →

Hearing Loss Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Sensorion, Fennec Pharma, Sound Pharma, Decibel Therapeutics, Akouos

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Hearing Loss pipeline constitutes 30+ key companies continuously working towards developing 35+ Hearing Loss treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes … Continue reading →